ArticleThe Journal of infectious diseases2010
Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.
Article in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Acute and Subacute Toxicity of Sialidase FromVeterinary medicine international · 2025Article
- Article
- Cationic Perylene Antivirals with Aqueous Solubility for Studies In Vivo.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Analysis Comparison for Rapid Identification of Pathogenic Virus from Infected Tissue Samples.Diagnostics (Basel, Switzerland) · 2022Article
- Advances in the development of entry inhibitors for sialic-acid-targeting viruses.Drug discovery today · 2021Review
- Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections WithFrontiers in cellular and infection microbiology · 2021Review
- Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus andFrontiers in immunology · 2020Review
- Bacterial sialoglycosidases in Virulence and Pathogenesis.Pathogens (Basel, Switzerland) · 2019Review
- Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.Journal of thoracic disease · 2018Review
- Treating Influenza Infection, From Now and Into the Future.Frontiers in immunology · 2018Review
- Antivirals for Respiratory Viral Infections: Problems and Prospects.Seminars in respiratory and critical care medicine · 2016Review
- The Effect of Probiotic Treatment on Patients Infected with the H7N9 Influenza Virus.PloS one · 2016Article
- Broad-spectrum antiviral agents.Frontiers in microbiology · 2015Review
- An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection.BMC infectious diseases · 2014Article
- Emerging antiviral strategies to interfere with influenza virus entry.Medicinal research reviews · 2014Review
- The use of sialidase therapy for respiratory viral infections.Antiviral research · 2013Review
- Review
- Viral and bacterial interactions in the upper respiratory tract.PLoS pathogens · 2013Review
- Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection.Antiviral research · 2012Review
- Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDAS181 (Fludase) is a sialidase fusion protein in clinical development as a broad-spectrum anti-influenza virus (IFV) therapeutic agent. Previous reports by other investigators have raised the concern that desialylation of airway epithelium might increase susceptibility to Streptococcus pneumoniae infection.
methodsTo address whether DAS181 would lead to an increased risk of pneumococcal infection, we tested S. pneumoniae colonization after DAS181 treatment of human A549 cells, healthy mice, and mice challenged with a lethal dose of IFV A/PR/8/34 (H1N1) or A/Victoria/3/75 (H3N2), followed by 10(4) cfu of S. pneumoniae (D39) on day 3 or day 7. DAS181 treatment was given 24-48 h after IFV challenge.
resultsDAS181 treatment did not increase S. pneumoniae colonization in vitro or in vivo in healthy animals. In IFV-infected mice, DAS181 prevented pneumonia and significantly prolonged survival and inhibited the IFV titer by > or = 3 logs. None of the treated animals showed enhanced S. pneumoniae colonization of the lung. In addition, opportunistic infections with Citrobacter species or Klebsiella species occurred only in mice receiving vehicle, not in animals treated with DAS181.
conclusionsThese data indicate that DAS181 treatment does not exacerbate secondary bacterial infection in mice. DAS181 may reduce the risk of secondary bacterial infection by inhibiting IFV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.